Ilankumaran Kaliamoorthy
Research Subjects
Ilankumaran Kaliamoorthy has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Rela
The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India
9 shared publications - Ashwin Rammohan
The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India
8 shared publications - Mettu Srinivas Reddy
Department of Liver Transplant and Hepatopancreaticobiliary Surgery, Gleneagles Global Health City, Perumbakkam, Chennai, India
6 shared publications - Mukul Vij
Institute of Liver Disease & Transplantation, Dr Rela Institute & Medical centre, Bharath Institute of Higher Education and Research, Chennai, India
5 shared publications - Rajesh Rajalingam
Department of HPB Surgery and Liver Transplantation, Institute of Liver Diseases and Transplantation, Dr. Rela Institute and Medical Centre, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India
4 shared publications - Abdul Rahman Hakeem
Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London SE5 9RS, United Kingdom.
3 shared publications
Latest Publications
- 20 May 2025
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 79, 152504
Granuloma rich hepatocellular carcinoma (GrHCC): Clinicopathologic and genomic characterization
- 20 May 2025
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 79, 152504
Granuloma rich hepatocellular carcinoma (GrHCC): Clinicopathologic and genomic characterization
- Open Access
- 24 November 2023
- Published by MDPI AG in Diagnostics
- Vol. 13  (23) , 3524
Update on the Pathology of Pediatric Liver Tumors: A Pictorial Review
Liver tumors in children are uncommon and show remarkable morphologic heterogeneity. Pediatric tumors may arise from either the epithelial or mesenchymal component of the liver and rarely may also show both lines of differentiation. Both benign and malignant liver tumors have been reported in children. The most common pediatric liver tumors by age are benign hepatic infantile hemangiomas in neonates and infants, malignant hepatoblastoma in infants and toddlers, and malignant hepatocellular carcinoma in teenagers. Here, we provide an up-to-date review of pediatric liver tumors. We discuss the clinical presentation, imaging findings, pathology, and relevant molecular features that can help in the correct identification of these tumors, which is important in managing these children.
- 24 November 2023
- Published by MDPI AG in Diagnostics
- Vol. 13  (23) , 3524
Open AccessUpdate on the Pathology of Pediatric Liver Tumors: A Pictorial Review
Liver tumors in children are uncommon and show remarkable morphologic heterogeneity. Pediatric tumors may arise from either the epithelial or mesenchymal component of the liver and rarely may also show both lines of differentiation. Both benign and malignant liver tumors have been reported in children. The most common pediatric liver tumors by age are benign hepatic infantile hemangiomas in neonates and infants, malignant hepatoblastoma in infants and toddlers, and malignant hepatocellular carcinoma in teenagers. Here, we provide an up-to-date review of pediatric liver tumors. We discuss the clinical presentation, imaging findings, pathology, and relevant molecular features that can help in the correct identification of these tumors, which is important in managing these children.
- 12 September 2023
- Published by Springer Nature in Hepatology International
- Vol. 18  (1) , 265-272
Propensity score matched analysis and risk stratification of donors with G6PD deficiency in living donor liver transplantation
Introduction Glucose 6 phosphate dehydrogenase (G6PD) deficiency (G6PDd) can trigger hemolysis following surgical stress. Differentiating G6PDd-related post-operative hemolytic episodes (PHE) and post-hepatectomy liver failure may be challenging especially in living donors where donor safety is paramount. We analysed outcomes of our cohort of G6PDd liver donors. Methods G6PDd individuals with no evidence of hemolysis were considered as living donors if there was no alternative family donor. Outcomes of G6PDd donors undergoing left lateral/left lobe donation (Group LL) and right lobe donation (Group RL) were compared with non-G6PDd donors matched in a 1:3 ratio using propensity score matching. Results 59 G6PDd donors (5.8% of 1011) underwent living donor hepatectomy (LiDH) during the study period. LL-G6PDd donors (22.37%) had higher post-operative peak bilirubin level compared to matched controls, but no difference in morbidity or need for post-operative blood transfusion.RL-G6PDd donors (37.63%) had higher peak bilirubin level, morbidity (16.2% vs. 3.6%, p = 0.017) and more post-operative blood transfusion (21.6% vs. 6.4%, p = 0.023) as compared to matched non-G6PDd cohort. Four RL-G6PDd donors (10.8%) developed PHE. Low G6PD activity (15% vs. 40%, p = 0.034) and lower future liver remnant (FLR) (34.3% vs. 37.8%, p = 0.05) were identified as risk factors for PHE. Conclusion We report the largest to-date series of G6PDd individuals undergoing LiDH and confirm the safety of LL donation in G6PDd. Our analysis identifies specific risk factors for PHE and suggests that right lobe LiDH be avoided in individuals with less than 25% G6PD activity when the FLR is less than 36%.
- 12 September 2023
- Published by Springer Nature in Hepatology International
- Vol. 18  (1) , 265-272
Propensity score matched analysis and risk stratification of donors with G6PD deficiency in living donor liver transplantation
Introduction Glucose 6 phosphate dehydrogenase (G6PD) deficiency (G6PDd) can trigger hemolysis following surgical stress. Differentiating G6PDd-related post-operative hemolytic episodes (PHE) and post-hepatectomy liver failure may be challenging especially in living donors where donor safety is paramount. We analysed outcomes of our cohort of G6PDd liver donors. Methods G6PDd individuals with no evidence of hemolysis were considered as living donors if there was no alternative family donor. Outcomes of G6PDd donors undergoing left lateral/left lobe donation (Group LL) and right lobe donation (Group RL) were compared with non-G6PDd donors matched in a 1:3 ratio using propensity score matching. Results 59 G6PDd donors (5.8% of 1011) underwent living donor hepatectomy (LiDH) during the study period. LL-G6PDd donors (22.37%) had higher post-operative peak bilirubin level compared to matched controls, but no difference in morbidity or need for post-operative blood transfusion.RL-G6PDd donors (37.63%) had higher peak bilirubin level, morbidity (16.2% vs. 3.6%, p = 0.017) and more post-operative blood transfusion (21.6% vs. 6.4%, p = 0.023) as compared to matched non-G6PDd cohort. Four RL-G6PDd donors (10.8%) developed PHE. Low G6PD activity (15% vs. 40%, p = 0.034) and lower future liver remnant (FLR) (34.3% vs. 37.8%, p = 0.05) were identified as risk factors for PHE. Conclusion We report the largest to-date series of G6PDd individuals undergoing LiDH and confirm the safety of LL donation in G6PDd. Our analysis identifies specific risk factors for PHE and suggests that right lobe LiDH be avoided in individuals with less than 25% G6PD activity when the FLR is less than 36%.
- 17 June 2023
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 66, 152172
Frequent expression of PD-L1 in lymphocyte-rich hepatocellular carcinoma: A report of 4 cases
- 17 June 2023
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 66, 152172
Frequent expression of PD-L1 in lymphocyte-rich hepatocellular carcinoma: A report of 4 cases
- 18 April 2023
- Published by Taylor & Francis in Fetal and Pediatric Pathology
- Vol. 42  (4) , 709-718
Pathologic and Immunophenotypic Characterization of Syncytial Giant Cell Variant of Pediatric Hepatocellular Carcinoma. A Distinct Subtype
Hepatocellular carcinoma (HCC) in pediatrics has a uniformly poor prognosis. Complete surgical resection or liver transplantation remain the only curative options. In contrast to adult HCC, literat...
- 18 April 2023
- Published by Taylor & Francis in Fetal and Pediatric Pathology
- Vol. 42  (4) , 709-718
Pathologic and Immunophenotypic Characterization of Syncytial Giant Cell Variant of Pediatric Hepatocellular Carcinoma. A Distinct Subtype
Hepatocellular carcinoma (HCC) in pediatrics has a uniformly poor prognosis. Complete surgical resection or liver transplantation remain the only curative options. In contrast to adult HCC, literat...
- Open Access
- 9 March 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23  (6) , 786-793
Anatomical variations of left hepatic vein and outflow reconstruction techniques in pediatric living donor liver transplantation
- 9 March 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23  (6) , 786-793
Open AccessAnatomical variations of left hepatic vein and outflow reconstruction techniques in pediatric living donor liver transplantation
- 7 September 2022
- Published by Wiley in World Journal of Surgery
- Vol. 46  (11) , 2806-2816
Living Donor Liver Transplantation for BuddâChiari Syndrome: A Propensity ScoreâMatched Analysis
Introduction: There are unique technical and management challenges associated with living donor liver transplantation (LDLT) for BuddâChiari Syndrome (BCS). The outcomes of LDLT for BCS in comparison to other indications remain unclear and warrant elucidation.Methods: Data of 24 BCS patients who underwent LDLT between January 2012 and June 2019 were analyzed. There were 20 adults and 4 children. The early and longâterm outcomes of adult LDLT BCS patients were compared to a control group of LDLT patients for other indications and matched using propensity scoring methodology.Results: Primary BCS was observed in 18 (90%) patients. Caval replacement was performed in 7 (35%) patients. Early and late hepatic venous outflow tract (HVOT) complications were seen in 1 (5%) and 3 (15%) patients. Preoperative acute kidney injury was identified as a risk factor for mortality in the BCS cohort (p = 0.013). On comparison, BCS recipients were younger with fewer comorbidities, more large volume ascites and higher rates of PVT. They also had longer cold ischemia time, increased blood loss and transfusion requirements, increased hospital stay, and higher late outflow complications. The 1âyear and 3âyear survivals were similar to nonâBCS cohort (84.2% vs. 94% and 71.3% vs. 91.9%, respectively, log rank test p = 0.09).Conclusion: LDLT is a good option for symptomatic BCS who have failed nonâtransplant interventions. The clinical and risk factor profile of BCS recipients is distinct from nonâBCS recipients. By following an algorithmic management protocol, we show on propensityâscore matched analysis that outcomes of LDLT for BCS are similar to nonâBCS indications.
- 7 September 2022
- Published by Wiley in World Journal of Surgery
- Vol. 46  (11) , 2806-2816
Living Donor Liver Transplantation for BuddâChiari Syndrome: A Propensity ScoreâMatched Analysis
Introduction: There are unique technical and management challenges associated with living donor liver transplantation (LDLT) for BuddâChiari Syndrome (BCS). The outcomes of LDLT for BCS in comparison to other indications remain unclear and warrant elucidation.Methods: Data of 24 BCS patients who underwent LDLT between January 2012 and June 2019 were analyzed. There were 20 adults and 4 children. The early and longâterm outcomes of adult LDLT BCS patients were compared to a control group of LDLT patients for other indications and matched using propensity scoring methodology.Results: Primary BCS was observed in 18 (90%) patients. Caval replacement was performed in 7 (35%) patients. Early and late hepatic venous outflow tract (HVOT) complications were seen in 1 (5%) and 3 (15%) patients. Preoperative acute kidney injury was identified as a risk factor for mortality in the BCS cohort (p = 0.013). On comparison, BCS recipients were younger with fewer comorbidities, more large volume ascites and higher rates of PVT. They also had longer cold ischemia time, increased blood loss and transfusion requirements, increased hospital stay, and higher late outflow complications. The 1âyear and 3âyear survivals were similar to nonâBCS cohort (84.2% vs. 94% and 71.3% vs. 91.9%, respectively, log rank test p = 0.09).Conclusion: LDLT is a good option for symptomatic BCS who have failed nonâtransplant interventions. The clinical and risk factor profile of BCS recipients is distinct from nonâBCS recipients. By following an algorithmic management protocol, we show on propensityâscore matched analysis that outcomes of LDLT for BCS are similar to nonâBCS indications.
- Open Access
- 1 October 2021
- Published by MDPI AG in Preprints.org
Living Donor Liver Transplantation for Budd-Chiari Syndrome: A Propensity Score-Matched Analysis
Introduction: There are unique technical and management challenges associated with living donor liver transplantation (LDLT) for Budd-Chiari Syndrome (BCS). The outcomes of LDLT for BCS in comparison to other indications remains unclear and warrants elucidation. Methods: Data of 24 BCS patients who underwent LDLT between January 2012 and June 2019 were analyzed. There were 20 adults and 4 children. The early and long-term outcomes of adult LDLT BCS patients were compared to a control group of LDLT patients for other indications and matched using propensity scoring methodology. Results: Primary BCS was observed in 22(91.7%) patients. Caval replacement was performed in 7(29.1%) patients. Early and late hepatic venous outflow tract (HVOT) complications were seen in 1(5.5%) and 3(16.7%) patients. Preoperative acute kidney injury was identified as a risk factor for mortality in the BCS cohort (p =0.013). On comparison, BCS recipients were younger with fewer comorbidities, more large volume ascites and higher rates of PVT. They also had longer cold ischemia time, increased blood loss and transfusion requirements, increased hospital stay, and higher late outflow complications. The 1-year and 3-year survivals were similar to non-BCS cohort (84.2% vs 94% and 70% vs 91.9%, respectively, log rank test p=0.09). Conclusion: LDLT is remains a good option for symptomatic BCS who have failed non-transplant interventions. The clinical and risk factor profile of BCS recipients is distinct from non-BCS recipients. By following an algorithmic management protocol, we show on propensity-score matched analysis that outcomes of LDLT for BCS are similar to non-BCS indications.
- 1 October 2021
- Published by MDPI AG in Preprints.org
Open AccessLiving Donor Liver Transplantation for Budd-Chiari Syndrome: A Propensity Score-Matched Analysis
Introduction: There are unique technical and management challenges associated with living donor liver transplantation (LDLT) for Budd-Chiari Syndrome (BCS). The outcomes of LDLT for BCS in comparison to other indications remains unclear and warrants elucidation. Methods: Data of 24 BCS patients who underwent LDLT between January 2012 and June 2019 were analyzed. There were 20 adults and 4 children. The early and long-term outcomes of adult LDLT BCS patients were compared to a control group of LDLT patients for other indications and matched using propensity scoring methodology. Results: Primary BCS was observed in 22(91.7%) patients. Caval replacement was performed in 7(29.1%) patients. Early and late hepatic venous outflow tract (HVOT) complications were seen in 1(5.5%) and 3(16.7%) patients. Preoperative acute kidney injury was identified as a risk factor for mortality in the BCS cohort (p =0.013). On comparison, BCS recipients were younger with fewer comorbidities, more large volume ascites and higher rates of PVT. They also had longer cold ischemia time, increased blood loss and transfusion requirements, increased hospital stay, and higher late outflow complications. The 1-year and 3-year survivals were similar to non-BCS cohort (84.2% vs 94% and 70% vs 91.9%, respectively, log rank test p=0.09). Conclusion: LDLT is remains a good option for symptomatic BCS who have failed non-transplant interventions. The clinical and risk factor profile of BCS recipients is distinct from non-BCS recipients. By following an algorithmic management protocol, we show on propensity-score matched analysis that outcomes of LDLT for BCS are similar to non-BCS indications.
- 31 March 2021
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 27  (9) , 1273-1282
Propensity ScoreâMatched Analysis of Posttransplant Outcomes in Living Donor Liver Transplantation for Older Adult Recipients
The impact of increasing recipient age on morbidity and mortality following living donor liver transplantation (LDLT) remains controversial. The study aims to analyze the impact of recipient age on outcomes following LDLT. Data on adult LDLTs performed between November 2009 and February 2020 were retrieved from a prospectively maintained database. Patients were stratified into 2 groups based on recipient age: 18 to 65 years (younger adults) and >65 years (older adults). Propensity score matching (PSM) using nearestâneighbor matching was used to match each older recipient with up to 2 younger adult recipients using multiple preoperative parameters. Outcomes evaluated were duration of ventilation, need for reintubation, tracheostomy, intensive care unit (ICU) readmission, length of ICU and hospital stays, postoperative complications, reoperation within 90 days, and patient survival. A total of 801 adult LDLT recipients were included in the study; 751 (93.7%) were younger adults, and 50 (6.3%) were older adults. Older recipients were more likely to be diabetic (60.0% versus 39.7%) and hypertensive (44.0% versus 20.4%) with preexisting cardiac disease (28.0% versus 11.2%). However, their pretransplant Model for EndâStage Liver Disease score was significantly lower (14.5 versus 17.7), and they were more likely to receive a transplant because of hepatocellular carcinoma (38.0% versus 17.7%). Older recipients had longer durations of ventilation after LT both before (3.7 versus 1.9 days) and after PSM (4.0 versus 1.5 days). After PSM, the 30âday (13.0% versus 2.4%), 90âday (15.2% and 2.4%), and overall mortality rates (21.7% versus 7.1%) were significantly higher for older recipients when compared with younger recipients. There was no difference between the younger and older recipients with respect to other postoperative outcomes. This propensity scoreâmatched study shows that the older LDLT recipients have higher 30âday, 90âday, 1âyear, and 5âyear mortality rates when compared with matched younger counterparts.
- 31 March 2021
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 27  (9) , 1273-1282
Propensity ScoreâMatched Analysis of Posttransplant Outcomes in Living Donor Liver Transplantation for Older Adult Recipients
The impact of increasing recipient age on morbidity and mortality following living donor liver transplantation (LDLT) remains controversial. The study aims to analyze the impact of recipient age on outcomes following LDLT. Data on adult LDLTs performed between November 2009 and February 2020 were retrieved from a prospectively maintained database. Patients were stratified into 2 groups based on recipient age: 18 to 65 years (younger adults) and >65 years (older adults). Propensity score matching (PSM) using nearestâneighbor matching was used to match each older recipient with up to 2 younger adult recipients using multiple preoperative parameters. Outcomes evaluated were duration of ventilation, need for reintubation, tracheostomy, intensive care unit (ICU) readmission, length of ICU and hospital stays, postoperative complications, reoperation within 90 days, and patient survival. A total of 801 adult LDLT recipients were included in the study; 751 (93.7%) were younger adults, and 50 (6.3%) were older adults. Older recipients were more likely to be diabetic (60.0% versus 39.7%) and hypertensive (44.0% versus 20.4%) with preexisting cardiac disease (28.0% versus 11.2%). However, their pretransplant Model for EndâStage Liver Disease score was significantly lower (14.5 versus 17.7), and they were more likely to receive a transplant because of hepatocellular carcinoma (38.0% versus 17.7%). Older recipients had longer durations of ventilation after LT both before (3.7 versus 1.9 days) and after PSM (4.0 versus 1.5 days). After PSM, the 30âday (13.0% versus 2.4%), 90âday (15.2% and 2.4%), and overall mortality rates (21.7% versus 7.1%) were significantly higher for older recipients when compared with younger recipients. There was no difference between the younger and older recipients with respect to other postoperative outcomes. This propensity scoreâmatched study shows that the older LDLT recipients have higher 30âday, 90âday, 1âyear, and 5âyear mortality rates when compared with matched younger counterparts.
- 3 September 2020
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 52  (2) , 766-770
Sinusoidal Hepatic Angiosarcoma on a Background of Non-cirrhotic Portal Hypertension and Nodular Regenerative Hyperplasia Masquerading as Acute on Chronic Liver Failure
- 3 September 2020
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 52  (2) , 766-770
Sinusoidal Hepatic Angiosarcoma on a Background of Non-cirrhotic Portal Hypertension and Nodular Regenerative Hyperplasia Masquerading as Acute on Chronic Liver Failure